New guidelines standardize diagnosis of canine dementia: full analysis
Veterinary teams now have the first published consensus guidelines for diagnosing and monitoring canine cognitive dysfunction syndrome, a condition that many clinicians recognize but have lacked a common framework to assess. The new recommendations, published in the Journal of the American Veterinary Medical Association, were developed by the Canine Cognitive Dysfunction Syndrome Working Group, an international panel that included specialists and primary care veterinarians, with leadership from NC State’s Dr. Natasha Olby. (pubmed.ncbi.nlm.nih.gov)
That framework arrives at a time when CCDS is becoming more visible in practice as dogs live longer and pet parents seek help for age-related behavior changes. Before these guidelines, there were no accepted diagnostic standards for CCDS, despite growing recognition that the syndrome shares clinical and pathologic features with Alzheimer’s disease in people. Existing tools, including caregiver questionnaires, have been useful but incomplete, because many CCDS-like signs can also be caused by chronic pain, sensory loss, endocrine or renal disease, or intracranial disorders. (pmc.ncbi.nlm.nih.gov)
The working group defines CCDS as a chronic, progressive, age-associated neurodegenerative syndrome marked by cognitive and behavioral changes that affect daily life. The guidelines organize those changes around the DISHAA framework: disorientation, altered social interactions, sleep-wake disruption, house soiling, changes in activity, and anxiety, with learning and memory also included in the syndrome’s behavioral profile. They propose three severity stages, from mild disease with subtle, low-frequency signs and preserved function to more advanced impairment, giving clinicians a common language for both diagnosis and follow-up. (pubmed.ncbi.nlm.nih.gov)
A key practical feature is the two-level diagnostic model. Level 1 is designed for everyday practice and centers on a compatible history of progressive DISHAA signs in an older dog, an abnormal CCDS scale score, physical, orthopedic, and neurologic examination, laboratory work to rule out competing diagnoses, and reassessment after management of relevant comorbidities. Level 2 adds MRI evidence of cortical atrophy and normal cerebrospinal fluid cell counts for cases where referral-level confirmation is needed, such as specialty settings or research. The guidelines also recommend annual behavioral screening beginning at age 7 and formal CCDS scale monitoring every 6 months starting at age 10. (pubmed.ncbi.nlm.nih.gov)
Industry and expert reaction has emphasized the value of finally having a shared standard. In the AKC Canine Health Foundation announcement tied to the publication, CEO Dr. Stephanie Montgomery said veterinary medicine needs more evidence-based standards, while working group member Dr. Gary Landsberg pointed to future priorities such as better diagnostic tests. The same announcement said CHF is partnering with Olby on an online CCDS resource hub, expected to launch in February 2026, to help veterinarians and pet parents access practical guidance. AAHA’s coverage also highlighted the real-world barriers behind the new framework, including limited appointment time, the lack of definitive in-clinic testing, and the difficulty of distinguishing CCDS from other neurologic disease. (akcchf.org)
Why it matters: For veterinary professionals, these guidelines could improve both case finding and case management. A recent U.S. survey found that 97.2% of veterinarians had diagnosed CCDS during their careers, yet most rarely or never referred suspected cases to specialists, and many reported uncertainty about treatment efficacy and best practices. In that context, a structured screening and staging system may help clinics build CCDS checks into senior wellness workflows, improve documentation in the medical record, and support clearer conversations with pet parents about prognosis, quality of life, and the need to rule out other causes before labeling a dog as demented. (pmc.ncbi.nlm.nih.gov)
The guidelines may also help research move faster. Because the recommendations standardize definitions, severity categories, and monitoring intervals, they could make future studies easier to compare across institutions. That matters in a field already exploring blood-based biomarkers such as neurofilament light chain and glial fibrillary acidic protein, though those tools are not yet ready to replace clinical diagnosis. For now, the message is more practical: screen earlier, use a consistent questionnaire, perform a careful neurologic and medical workup, and track change over time rather than relying on a single impression. (pubmed.ncbi.nlm.nih.gov)
What to watch: The next phase will be uptake in primary care, rollout of the AKC CHF resource hub, and follow-on research aimed at validating biomarkers and clinic-friendly cognitive tests that could sharpen diagnosis and monitoring beyond history and exclusion alone. (akcchf.org)